Goldman Sachs initiated coverage of Sigma Healthcare (SIGGF) with a Buy rating and A$3.50 price target The firm sees upside the company’s margin estimates and the stock’s valuation.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SIGGF:
- Sigma Healthcare: Undervalued Growth Leveraging Operating Scale, Private Label Expansion, and International Pharmacy Opportunities
- Sigma Healthcare Issues 2.4 Million Unquoted Performance Rights Under Employee Incentive Scheme
- Sigma Healthcare Grants Additional Performance Rights to Director Mario Verrocchi
- Sigma Healthcare Grants Long-Term Incentive Rights to Director Danielle Di Pilla
- Sigma Healthcare Grants Additional Long-Term Incentive Rights to CEO Vikesh Ramsunder